PayPal Increases Stake in German E-Commerce Platform Shopware to 41%
PayPal acquires additional shares in Shopware AG from Carlyle Group, boosting its ownership from 11% to 41% in the German digital commerce company.
NOTRELOAD AI
Perspective Therapeutics Stock Plunges 29% Despite 'Remarkable' Safety Data from Cancer Drug Trial
Perspective Therapeutics shares fell 29% to $3.19 after presenting Phase 1/2a trial data for VMT-alpha-NET. Analysts split on outlook despite favorable safety profile and $174M cash position through late 2026.
Neuphoria's Social Anxiety Treatment Fails Phase 3 Trial
Neuphoria's AFFIRM-1 Phase 3 trial for BNC210 social anxiety treatment misses all endpoints. Company halts SAD program, reviews options.
Raymond James Launches MeiraGTx Coverage with Strong Buy Rating
Raymond James initiates MeiraGTx with Strong Buy rating and $29 price target, highlighting company's manufacturing platform and two major commercial opportunities in xerostomia and Parkinson's disease.
William Blair Maintains Buy Rating on Exelixis Following Positive Cancer Trial Results, Despite Safety Concerns
William Blair analyst Andy Hsieh reaffirms Buy rating on EXEL stock after Phase III trial shows zanzalintinib combination therapy improves survival in metastatic colorectal cancer patients.
Morgan Stanley Maintains Bullish Stance on Elf Beauty Despite Rhode's Q2 Miss
Morgan Stanley analyst remains confident in Elf Beauty's growth despite Rhode brand's lower-than-expected June quarter revenue, citing strong September Sephora launch and maintaining $170 target.